All Stories

  1. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin
  2. Small Molecule Inhibitors of Clostridium difficile Toxin B-Induced Cellular Damage
  3. Mechanisms of Protection against Clostridium difficile Infection by the Monoclonal Antitoxin Antibodies Actoxumab and Bezlotoxumab
  4. Broad Coverage of Genetically Diverse Strains of Clostridium difficile by Actoxumab and Bezlotoxumab Predicted byIn VitroNeutralization and Epitope Modeling
  5. Production of Tissue-Engineered Human 3D Bronchi In Vitro
  6. Toxin-Mediated Paracellular Transport of Antitoxin Antibodies Facilitates Protection against Clostridium difficile Infection
  7. Prevention of Clostridium difficile infections—The role of vaccines and therapeutic immunoglobulins
  8. Clostridium difficile toxin B CROP domain in complex with FAB domains of neutralizing antibody bezlotoxumab
  9. Mechanism of Action and Epitopes of Clostridium difficile Toxin B-neutralizing Antibody Bezlotoxumab Revealed by X-ray Crystallography
  10. Gene expression profiling following NRF2 and KEAP1 siRNA knockdown in human lung fibroblasts identifies CCL11/Eotaxin-1 as a novel NRF2 regulated gene
  11. Naphthalene/quinoline amides and sulfonylureas as potent and selective antagonists of the EP4 receptor
  12. A novel series of potent and selective EP4 receptor ligands: Facile modulation of agonism and antagonism
  13. The identification of substituted benzothiophene derivatives as PGE2 subtype 4 receptor antagonists: From acid to non-acid
  14. Discovery of 4-{1-[({1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl}carbonyl)amino]cyclopropyl}benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain
  15. The Discovery of 4-{1-[({2,5-Dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic Acid (MK-2894), A Potent and Selective Prostaglandin E 2 Subtype 4 Receptor Antagonist †
  16. Mutual antagonistic relationship between prostaglandin E2and IFN‐γ: Implications for rheumatoid arthritis
  17. Adenovirus IL-13–Induced Airway Disease in Mice
  18. Structure–activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP4 receptor
  19. The C3a receptor antagonist SB 290157 has agonist activity
  20. Non-Native Interhelical Hydrogen Bonds in the Cystic Fibrosis Transmembrane Conductance Regulator Domain Modulated by Polar Mutations †
  21. Missense mutations in transmembrane domains of proteins: Phenotypic propensity of polar residues for human disease
  22. Oligomerization of a Peptide Derived from the Transmembrane Region of the Sodium Pump γ Subunit: Effect of the Pathological Mutation G41R
  23. Expression and Purification of Two Hydrophobic Double-Spanning Membrane Proteins Derived from the Cystic Fibrosis Transmembrane Conductance Regulator
  24. Putting the β-breaks on membrane protein misfolding
  25. Polar mutations in membrane proteins as a biophysical basis for disease
  26. Interhelical Packing in Detergent Micelles: FOLDING OF A CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CONSTRUCT
  27. Effect of Detergents on Intramolecular Helix-Helix Packing in a Membrane-Based Peptide Derived from CFTR
  28. Expression and Functional Role of the   Subunit of the Na,K-ATPase in Mammalian Cells
  29. Tissue-specific Distribution and Modulatory Role of the   Subunit of the Na,K-ATPase